Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K current report with the SEC on November 17, 2026 reporting Item 3.01 (Notice of Delisting). Nasdaq bid-price deficiency after 30 consecutive business days below the $1.00 minimum.
- This filing includes Item 3.01, an item that often signal trouble.
Aldeyra Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.01 · Notice of Delisting
- Nasdaq bid-price deficiency after 30 consecutive business days below the $1.00 minimum
- No immediate delisting, Nasdaq listing remains effective
- Initial compliance deadline: May 17, 2027, requiring at least $1.00 closing bid for 10 consecutive business days
- Potential second 180-day grace period, contingent on market-value and other listing requirements
- Delisting risk may increase trading disruption, liquidity pressure and investor concern if compliance is not restored
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aldeyra Therapeutics, Inc. 8-K filings
Get the next ALDX 8-K as it lands
Follow ALDX for push alerts, or ask the research agent what this filing means.